Isotopia Molecular Imaging ltd’s Post

Radiopharma CDMOs navigate supply chain, raw material challenges as demand goes nuclear >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #biotech #pharma #pharmaceutical

Dr. Jagadeesh Bharatam and his team at the CSIR-INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY use Nuclear Magnetic resonance (#NMR) to study the structural properties, impurities, and polymorphs of drug formulations in solid and solution states, with applications in drug evaluation, characterization, and design. They are also collaborating with #Bruker to advance the field of solid-state NMR with novel techniques such as Hadamard NMR spectroscopy. To read more and learn how NMR can enhance pharmaceutical research, download the article (PDF) here: https://lnkd.in/dDQ5XH5f #CustomerInsights #Pharmaceuticals #Pharma

Check out this new video of our DH Lifelabs Sciaire H100 Air Ion Generator. Perfect for whole home air purification of particulates, gases, and biologics.

This whitepaper from Bruker available in the European Pharmaceutical Review, details how solutions such as their Fourier PAT benchtop combine the insightful revelations leveraged from NMR spectroscopy with Process Analytical Technology (PAT), to improve advanced operations in (bio) pharmaceutical manufacturing. Find out more here: https://lnkd.in/dEHhuWxg #ProcessAnalyticalTechnology #NMRSpectroscopy #PharmaceuticalIndustry #SmartManufacturing

𝗘𝗹𝘂𝗰𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗧𝗮𝗿𝘁𝗮𝗿𝗶𝗰 𝗔𝗰𝗶𝗱-𝗔𝘀𝘀𝗶𝘀𝘁𝗲𝗱 𝗦𝘂𝗽𝗲𝗿𝘀𝗮𝘁𝘂𝗿𝗮𝘁𝗶𝗼𝗻 𝗠𝗮𝗶𝗻𝘁𝗲𝗻𝗮𝗻𝗰𝗲 𝗼𝗳 𝗗𝗶𝗽𝘆𝗿𝗶𝗱𝗮𝗺𝗼𝗹𝗲 𝗯𝘆 𝗘𝘂𝗱𝗿𝗮𝗴𝗶𝘁® 𝗘𝟭𝟬𝟬 The purpose of this study was to investigate the effect of tartaric acid on the maintenance of dipyridamole supersaturation using Eudragit E100 as a carrier. Learn more here: https://lnkd.in/efzRdkZy #excipients #eudragit #pharmaceuticals Evonik Health Care PharmaExcipients.com

🔗rizochem.com 🔗rizochem.ae Top Pharmaceuticals Wholesaler, Distributor & Exporter Company from India Rizochem is the top renowned third-party pharmaceutical wholesaler & exporter company from India. We have been giving our best services since 2011. Rizochem works as a Distributor of medicines to many institutions like the Nuclear Power Corporation of India, Hospital of India Railways, etc. #company #pharmacy #pharmacylife #medicaments #medicamento #medicamentos #remedy #capsules #pharmacy #pharmacist #pharma #pharmacylife #distributor #distributors #pharmacology See less

🔗rizochem.com 🔗rizochem.ae Top Pharmaceuticals Wholesaler, Distributor & Exporter Company from India Rizochem is the top renowned third-party pharmaceutical wholesaler & and exporter company from India. We have been giving our best services since 2011. Rizochem works as a Distributor of medicines to many institutions like the Nuclear Power Corporation of India, Hospital of India Railways, etc. #company #pharmacy #pharmacylife #medicaments #medicamento #medicamentos #remedy #capsules #pharmacy #pharmacist #pharma #pharmacylife #distributor #distributors #pharmacology See less

4 powerful technologies all in one platform. Are you looking to characterize the stability of your biologics pipeline? If so, let’s have a conversation!

Good summary of key CDMO industry news from DCAT two weeks ago in the link below. I also thought I’d take it as an opportunity to provide my Key Takeaways from the DCAT Conference. What do you think? ** Market Recovery is a Mixed Bag**: Number 1 topic of conversation in my meetings. Early-stage emerging Biotechs, and CRO/CDMO’s who service them, are still feeling the pinch. Will likely continue through 2024. Biotechs with mid-phase clinical to commercial assets are getting more VC funding and IPO’s picking up. The CDMO’s who cater to these clients are seeing more stability and growth. ** BIOSECURE Act and BIO’s Abrupt Reversal**: Number 2 topic of conversation in my meetings. More questions than answers on Wuxi and China. All to do about nothing, or tip of the iceberg? Highlights continued entanglement with China/supply chains. A materially large percentage of US biopharma are using China-HQ’d CRO/CDMO’s. Can’t just abruptly stop; will hurt US innovators in the near/mid-term. Lots of US CRO/CDMO’s positioning now. What are VC firms saying to their biotech portfolio’s about offshoring given the current news here? Would love to be a fly on the wall……… ** If Activity is Any Indicator**: I don’t think I’ve ever seen that many people packed into the Intercontinental Lobby during DCAT. Everyone I met with (Biotechs, Investment Banks, CRO/CDMO’s, Market consultants) cited an unusual level of action and activity this DCAT. Not sure how much of that translated into deals consummated, but most everyone was optimistic for 2024 as a year of stabilization (vs past 2 years), and likely a more meaningful rebound in 2025. I’d tend to agree. ** ADC’s, Nuclear Medicine, and Bi-Specifics all Hot"": In my meetings these three therapeutic modalities got the most coverage. Investment in infrastructure to support these therapeutics continues at a strong pace. ** Big Surprise – Large Volume API Investments in the US**: I spoke to a couple of North American CDMO’s who had cited large expansion projects to support launches of large volume small molecules here in the US. These were 4000 gallon reactor scale which is exceptionally large (50-100MT volumes). I found it interesting since most new therapeutics are more targeted, lower volumes. Good to see large scale investment here in the US.